Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury.

@article{Kolkhof2014FinerenoneAN,
  title={Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury.},
  author={Peter Kolkhof and Martina Delbeck and Axel Kretschmer and Wolfram Steinke and Elke C. Hartmann and Lars B{\"a}rfacker and Frank Eitner and Barbara E. Albrecht-K{\"u}pper and Stefan B. Sch{\"a}fer},
  journal={Journal of cardiovascular pharmacology},
  year={2014},
  volume={64 1},
  pages={69-78}
}
Pharmacological blockade of the mineralocorticoid receptor (MR) ameliorates end-organ damage in chronic heart failure. However, the clinical use of available steroidal MR antagonists is restricted because of concomitant hyperkalemia especially in patients with diminished kidney function. We have recently identified a novel nonsteroidal MR antagonist, finerenone, which uniquely combines potency and selectivity toward MR. Here, we investigated the tissue distribution and chronic cardiorenal end… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS
37 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 37 extracted citations

Similar Papers

Loading similar papers…